Metformin lowers serum cobalamin levels in up to one in ten patients, and that deficiency is treatable without stopping the medication. At Longevity Benchmark, we review clinical trial data and regulatory guidance to help readers identify preventable nutrient depletions while keeping evidence-based prescriptions in place. Regular blood surveillance and targeted supplementation resolve this depletion while preserving your established metabolic therapy.
The Verdict
Vitamin B12 Deficiency Metformin Label Warnings and Clinical Prevalence
Metformin lowers circulating cobalamin. The FDA label reports subnormal B12 in about 7 percent of patients across 29-week trials, and the MHRA classes deficiency as a common reaction affecting up to 1 in 10 people taking metformin. The official Food and Drug Administration (FDA) label for metformin hydrochloride tablets explicitly addresses this risk in Section 5.2: "Metformin may lower vitamin B12 levels. Measure hematologic parameters on an annual basis and vitamin B12 at 2 to 3 year intervals in patients on metformin hydrochloride tablets and manage any abnormalities." Section 6.1 adds that clinical trials of 29-week duration documented a decrease to subnormal levels of previously normal serum B12 in approximately 7 percent of patients.
Safety alerts from the Medicines and Healthcare products Regulatory Agency (MHRA) classify vitamin B12 deficiency as a common adverse drug reaction affecting up to 1 in 10 people taking metformin. Long-term follow-up from the Diabetes Prevention Program Outcomes Study (DPPOS) published by Aroda and colleagues in 2016 found that low B12 (at or below 203 pg/mL) occurred in 4.3 percent of metformin users at five years compared to 2.3 percent on placebo. That same trial observed combined low and borderline B12 levels (at or below 298 pg/mL) in 19.1 percent of participants on metformin versus 9.5 percent in the placebo group.
Despite these published rates, real-world primary care coding often misses early biochemical drops. A UK primary care analysis of roughly 148,000 patients across nine medical practices found documented deficiency coding in just 0.25 percent of metformin users. Although the proportion of patients tested rose from 34.5 percent to 38.2 percent after updated guidance, the vast majority of at-risk individuals remain unscreened until symptoms prompt investigation.
Metformin Absorption Mechanisms and Long-Term Trial Evidence
Metformin impairs cobalamin uptake in the distal ileum through a dose-dependent, calcium-dependent process. The FDA package insert states that this decrease is "possibly due to interference with B12 absorption from the B12-intrinsic factor complex." A classic clinical investigation by Bauman and colleagues demonstrated that ileal cell surface receptors require free calcium to internalize the cobalamin-intrinsic factor complex, and metformin alters cell membrane electrical charges to displace available calcium ions.
The risk of developing subnormal levels increases steadily with cumulative drug exposure. In the DPPOS cohort, researchers calculated an odds ratio of 1.13 per additional year of metformin therapy, reflecting a continuous rise in deficiency risk over time. The American Academy of Family Physicians (AAFP) evaluated these findings and reported a number needed to harm of 14 per 4.3 years for clinical deficiency, and 9 per 4.3 years for low B12 levels.
Correcting this nutrient deficit does not require discontinuing a medication that maintains glycemic control and metabolic stability. The FDA label states the decrease appears to be rapidly reversible with discontinuation of metformin or with vitamin B12 supplementation, and supplementation is the route that keeps the drug running. Because metformin delivers established vascular benefits and improves HbA1c control, the deficit is corrected with B12 replacement rather than by changing the drug. NICE NG239 recommendation 1.3.4 says to take the blood sample before replacement starts, so a supplement begun beforehand makes the result uninterpretable.
Acid Suppression From Proton Pump Inhibitors and H2 Blockers
Long-term use of gastric acid suppressants inhibits the enzymatic release of vitamin B12 from dietary animal proteins. Dietary cobalamin enters the stomach bound tightly to food matrices, requiring hydrochloric acid and pepsin to release the free vitamin so it can bind gastric transport proteins. By elevating intragastric pH, proton pump inhibitors (PPIs) such as omeprazole and histamine-2 (H2) receptor antagonists hinder this necessary uncoupling step.
Observational datasets indicate an increased statistical likelihood of deficiency among chronic users. A large nested case-control study by Lam and colleagues in JAMA evaluated 25,956 deficiency cases and 184,199 controls, identifying an adjusted odds ratio of 1.65 for individuals using PPIs for two or more years. That study found a clear dose gradient: taking less than 0.75 pills daily carried an odds ratio of 1.63, while taking 1.5 or more pills daily raised the odds ratio to 1.95. For H2-receptor antagonists, two or more years of use produced an odds ratio of 1.25.
In contrast, a 2025 systematic review and meta-analysis of six studies published in PMC examined 4,413 participants and found no statistically detectable association between chronic PPI use and serum B12 concentrations or homocysteine levels. The meta-analysis authors recommended against universal screening for healthy, well-nourished individuals on acid suppression. They advised reserving routine blood surveillance for high-risk populations, such as elderly or malnourished patients whose physiological reserves are already limited.
Rapid Inactivation of Cobalamin by Nitrous Oxide
Nitrous oxide causes acute functional vitamin B12 deficiency by directly oxidizing the cobalt core of the cobalamin molecule. A scientific review in PMC explains that the gas oxidizes the cobalt ion from its active monovalent (Co+) state into inactive bivalent (Co2+) and trivalent (Co3+) forms. This chemical transformation inactivates methionine synthase, halting the synthesis of methionine from homocysteine and disrupting myelin sheath maintenance.
Because nitrous oxide inactivates circulating cobalamin rather than slowly draining hepatic stores, serum B12 blood levels often remain completely normal. In a German hospital series published in PMC tracking 20 patients with severe nitrous oxide toxicity, 95 percent displayed normal serum B12 levels, yet 100 percent presented with elevated homocysteine and 95 percent had elevated methylmalonic acid (MMA). All 20 individuals developed sensory deficits and 85 percent had gait disturbances. Of the 15 patients who had spinal imaging, 11 (73.3 percent) showed T2-hyperintense cord lesions.
Recreational inhalation of pressurized 8-gram culinary whipped cream chargers has emerged as a frequent source of acute neurotoxicity. According to StatPearls, approximately 3.4 percent of recreational users experience neurological symptoms, and the substance represents the second most common recreational drug among 16 to 24 year olds in the UK. Because standard blood tests mislead clinicians, NICE guideline NG239 recommendation 1.3.3 mandates using plasma homocysteine or serum MMA as the initial diagnostic test for suspected nitrous oxide toxicity.
Surgical Alterations to the Gastrointestinal Absorption Pathway
Surgical alteration of the stomach or small intestine disrupts the specialized physical stages required for cobalamin uptake. Physiological absorption depends on gastric acid to unbind food protein, intrinsic factor from parietal cells to protect the vitamin, and mucosal receptors in the terminal ileum to absorb the complex. Removing or bypassing any of these anatomical segments creates permanent malabsorption that oral dietary intake cannot overcome.
Different surgical procedures carry distinct nutritional depletion risks based on the specific segments altered. A comparative trial in PMC evaluated 505 bariatric patients, documenting a 12-month deficiency rate of 16.74 percent after Roux-en-Y gastric bypass compared to only 0.93 percent following sleeve gastrectomy. Over a 10-year period in the SLEEVEPASS trial, deficiency rates converged between procedures primarily because patient adherence to oral supplementation declined.
Clinical guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) note that baseline deficiency exists in 2 to 18 percent of candidates before surgery, and reaches 6 to 30 percent in chronic PPI users. Because the Merck Manual Professional puts liver B12 stores at 3 to 5 years of normal need once intake stops, clinical deficiency often surfaces years after the operation. StatPearls documents cases of subacute combined degeneration developing up to 12 years following total gastrectomy when maintenance therapy was neglected.
| Surgical Procedure | Anatomical Disruption | Reported Deficiency Rate | Surveillance and Repletion Guidelines |
|---|---|---|---|
| Total gastrectomy | Complete resection of gastric parietal cells and intrinsic factor production. | Approaches 100 percent without lifelong medical replacement. | NICE NG239 recommendation 1.5.3 mandates lifelong intramuscular B12 injections. |
| Roux-en-Y gastric bypass | Small gastric pouch bypasses parietal cells, duodenum, and upper jejunum. | Reported under 20 percent at 2 to 5 years; 16.74 percent at 12 months in cohort trials. | ASMBS recommends 350 to 500 mcg oral daily or 1,000 mcg monthly intramuscularly, with annual screening. |
| Sleeve gastrectomy | Resection of gastric fundus and body, reducing total parietal cell mass. | Reported 4 to 20 percent at 2 to 5 years; 0.93 percent at 12 months in cohort trials. | ASMBS recommends 350 to 500 mcg oral daily, with screening every 3 months in year one, then annually. |
| Terminal ileal resection | Loss of mucosal cubam receptors and specialized enterocytes in distal ileum. | High risk proportional to the length of terminal ileum resected. | NICE NG239 recommendation 1.5.3 mandates lifelong intramuscular injections if resection is complete. |
GLP-1 Receptor Agonists and Concomitant Metformin Therapy
Current clinical evidence does not identify glucagon-like peptide-1 (GLP-1) receptor agonists as independent drivers of cobalamin deficiency. The comprehensive NICE guideline NG239 Box 2 lists multiple medication classes known to induce B12 deficiency, but omits GLP-1 receptor agonists entirely. No source reviewed for this page establishes a B12 effect for semaglutide or tirzepatide independent of metformin.
Real-world observational registries that report nutritional depletions among GLP-1 users generally reflect concomitant drug regimens. A retrospective study of 461,382 adults published in PMC identified overall nutritional deficiencies in 12.7 percent of patients within six months and 22.4 percent within twelve months. However, that study grouped B12 into a broad category and propensity-matched GLP-1 users against controls who were also prescribed metformin, meaning both cohorts carried the established metformin exposure.
The study authors explicitly noted that observational billing codes cannot demonstrate direct pharmacological causation or capture over-the-counter dietary supplement habits. For individuals taking a GLP-1 receptor agonist in combination with metformin, the verified driver of B12 reduction remains the metformin component. Patients using these therapies together should follow standard metformin monitoring schedules without altering their prescribed doses.
Additional Medications Associated With B12 Depletion
Several other common prescription medications alter intestinal cobalamin uptake or distort blood test measurements. NICE guideline NG239 Box 2 identifies colchicine, phenobarbital, pregabalin, primidone, and topiramate as established medicine risk factors for B12 deficiency. Additionally, MedlinePlus notes that phenytoin, neomycin, and para-aminosalicylic acid can influence laboratory test values.
Laboratory research shows that the gout medication colchicine causes acute, reversible damage to mucosal transport receptors. In a study published in Gastroenterology, animal models receiving colchicine experienced a dose-dependent reduction in intrinsic factor-B12 mucosal receptors from 5.78 ng down to 1.3 ng within three days. Following drug discontinuation, the concentration of mucosal receptors and the quantity of absorbed B12 rebounded to supranormal levels during tissue recovery.
Alcohol-induced B12 malabsorption in humans was described as early as 1969, in a Nature paper titled "Alcohol-induced malabsorption of vitamin B12 in man". No effect size, dose, duration or mechanism from that work could be verified for this page, and alcohol does not appear on the NICE NG239, MHRA or ASMBS medicine lists.
Clinical Monitoring for Vitamin B12 Deficiency Metformin Patients
Establishing structured laboratory surveillance detects declining cobalamin reserves before hematological or neurological damage occurs. The FDA metformin drug label instructs clinicians to check complete blood counts annually and assess serum vitamin B12 at 2 to 3 year intervals. The MHRA advises testing whenever symptoms such as unexplained fatigue or paresthesias appear, with periodic monitoring for patients carrying additional gastrointestinal or dietary risk factors.
Who this protocol is not for: Patients who have undergone total gastrectomy or complete terminal ileal resection cannot rely on routine oral multivitamin tablets. Because these operations remove specialized parietal cells or ileal enterocytes, NICE guideline NG239 mandates lifelong intramuscular injections managed directly by a specialist physician. For other patients with indeterminate blood test results, our guide on vitamin B12 testing protocols details when to order methylmalonic acid to confirm functional deficiency.
What would change our guidance on acid suppressants: If randomized controlled trials establish that long-term proton pump inhibitors cause clinically meaningful functional deficiency in healthy, non-elderly adults, universal annual screening would become appropriate for all chronic users. Under current guidelines, NICE recommendation 1.5.6 advises offering oral or intramuscular B12 replacement while the offending medication continues, followed by a clinical review at three months. Ask your prescribing physician for a serum cobalamin and a complete blood count at your next annual review, to screen for metformin-related vitamin B12 deficiency without interrupting your current medication.
| Guideline Body | Target Population | Testing Schedule | Recommended Clinical Action |
|---|---|---|---|
| FDA Metformin Label | Patients taking metformin hydrochloride tablets. | Complete blood count annually; serum B12 every 2 to 3 years. | Manage abnormalities with oral B12 supplementation while maintaining drug therapy. |
| MHRA Safety Guidance | Patients taking metformin with symptoms or additional risk factors. | Test on symptom suspicion; consider periodic checks with risk factors. | Review concomitant medications and initiate replacement therapy as clinically indicated. |
| ASMBS Bariatric Guidelines | Post-bariatric surgery patients (RYGB, sleeve gastrectomy, BPD/DS). | Every 3 months in year one; annually thereafter (or more often if on depleting drugs). | Supplement 350 to 500 mcg oral daily or 1,000 mcg monthly intramuscularly; treat deficiency with 1,000 mcg daily. |
| NICE Guideline NG239 | Patients taking medications that cause B12 deficiency as a side effect. | Test upon symptom suspicion or relevant risk profile. | Offer oral or intramuscular replacement while continuing drug; review response at 3 months. |
Frequently Asked Questions
Does metformin cause vitamin B12 deficiency?
Yes, metformin lowers circulating vitamin B12 levels in roughly 7 percent to 10 percent of patients who take it long term. The official Food and Drug Administration label notes that clinical trials documented subnormal B12 levels in approximately 7 percent of participants within 29 weeks. The Medicines and Healthcare products Regulatory Agency categorizes B12 deficiency as a common adverse reaction affecting up to 1 in 10 users. In the Diabetes Prevention Program Outcomes Study, low B12 (at or below 203 pg/mL) occurred in 4.3 percent of metformin users at five years, compared to 2.3 percent on placebo. The depletion occurs because metformin interferes with calcium-dependent absorption of the cobalamin-intrinsic factor complex in the distal ileum. The depletion is correctable with oral supplementation while metformin continues, once a baseline blood test has been taken.
How long does metformin take to cause B12 deficiency?
Metformin-induced B12 deficiency typically develops over two to five years, though biochemical drops can emerge within months. In clinical trials cited on the Food and Drug Administration label, subnormal serum levels appeared in approximately 7 percent of patients within 29 weeks of starting therapy. Because liver B12 stores can sustain normal needs for 3 to 5 years once intake stops, per the Merck Manual Professional, overt clinical symptoms develop slowly as those reserves run down. In the Diabetes Prevention Program Outcomes Study, the gap between metformin and placebo users was widest at five years, when 19.1 percent of metformin users had low or borderline levels compared to 9.5 percent on placebo. Researchers identified an odds ratio of 1.13 for deficiency per year of use, demonstrating that the likelihood of deficiency compounds steadily over time.
Should I take a B12 supplement with metformin?
You should consult your prescribing physician about taking a supplemental B12 dose, especially if your dietary intake is low or you take metformin long term. The official Food and Drug Administration package insert states that individuals with inadequate dietary B12 or calcium intake are predisposed to subnormal levels. The label also confirms that metformin-induced depletion is rapidly reversible with oral vitamin B12 supplementation. Under National Institute for Health and Care Excellence guideline NG239, clinicians can offer oral or intramuscular replacement while your metformin therapy continues uninterrupted. Have the blood drawn first. NICE NG239 recommendation 1.3.4 says to take diagnostic samples before replacement begins, because a supplement started beforehand raises serum B12 without treating the cause and leaves the result uninterpretable.
Do proton pump inhibitors cause B12 deficiency?
Long-term proton pump inhibitor therapy modestly increases the risk of B12 deficiency, primarily after two or more years of continuous daily use. Dietary vitamin B12 is bound to animal proteins and requires stomach acid and pepsin to become free for absorption. By suppressing gastric acid, medications like omeprazole impair this enzymatic separation. In a large nested case-control study published in JAMA, taking a proton pump inhibitor for two or more years was associated with an odds ratio of 1.65 for deficiency. However, a 2025 systematic review of six trials found no detectable change in serum B12 concentrations among chronic users. Consequently, guidelines do not recommend universal screening for healthy individuals on acid suppressants, but suggest monitoring high-risk elderly or malnourished patients.
Do GLP-1 medications cause B12 deficiency?
There is no clinical trial evidence demonstrating that glucagon-like peptide-1 receptor agonists cause vitamin B12 deficiency. National Institute for Health and Care Excellence guideline NG239 does not list GLP-1 medications among the pharmacological risk factors for cobalamin depletion. While a retrospective observational analysis of 461,382 patients noted general nutritional depletions in some GLP-1 users, the participants were also taking metformin, which was present in both comparison cohorts. The authors explicitly stated their observational findings could not prove a causal relationship. The widely repeated theory that delayed gastric emptying reduces B12 absorption is not supported by any primary source reviewed for this page. If you take a GLP-1 medication alongside metformin, your B12 surveillance should follow standard metformin protocols.
Why does nitrous oxide cause B12 deficiency?
Nitrous oxide causes rapid, functional vitamin B12 deficiency by chemically oxidizing the cobalt ion within active cobalamin molecules. The gas converts monovalent cobalt into inactive bivalent and trivalent states, disabling the enzyme methionine synthase. This halts the conversion of homocysteine to methionine and disrupts the synthesis of myelin sheaths protecting the nervous system. Because nitrous oxide inactivates existing cobalamin rather than draining liver stores, standard total serum B12 blood tests usually appear deceptively normal. In a clinical series of 20 hospitalized patients with severe toxicity, 95 percent showed normal serum B12, yet 100 percent had elevated homocysteine and 95 percent had elevated methylmalonic acid. National Institute for Health and Care Excellence guideline NG239 mandates testing methylmalonic acid or homocysteine when evaluating suspected nitrous oxide neurotoxicity.
Do I need B12 after gastric bypass surgery?
Yes, all patients require lifelong vitamin B12 supplementation following Roux-en-Y gastric bypass surgery. Gastric bypass constructs a small stomach pouch that bypasses the lower stomach and duodenum, dramatically decreasing the secretion of intrinsic factor and gastric acid required for cobalamin uptake. Clinical guidelines from the American Society for Metabolic and Bariatric Surgery recommend that all post-bypass patients take 350 to 500 micrograms of B12 daily as an oral disintegrating tablet, liquid, or sublingual tablet, or receive 1,000 micrograms monthly through intramuscular injections. Bariatric guidelines also recommend checking B12 levels every 3 months during the first year after surgery, and at least annually thereafter. Failing to supplement can result in severe, irreversible nerve damage years after surgery once existing liver reserves run out.
How often should my B12 be checked on metformin?
According to the official Food and Drug Administration label, patients taking metformin hydrochloride tablets should have hematologic parameters measured annually and serum vitamin B12 assessed every 2 to 3 years. The Medicines and Healthcare products Regulatory Agency in the United Kingdom recommends testing whenever patients report symptoms of deficiency, such as fatigue, paresthesias, or numbness, and advises periodic monitoring for patients with risk factors like vegetarian diets or concurrent acid suppressant use. The American Society for Metabolic and Bariatric Surgery recommends at least annual testing for post-surgical patients taking metformin. If your initial total B12 level lands in a borderline grey zone, your physician may order a reflex methylmalonic acid or homocysteine test to evaluate cellular cobalamin activity accurately.